Patients whose atrial fibrillation lasts longer than seven days and who do not respond well to drug therapy are now eligible ...

The global healthcare and laboratory labels market share analysis is projected to exceed USD 11,219.8 million by 2035, ...

The anti-GPC3 targeted therapies market is expected to witness growth in the coming years, driven by the increasing incidence of cancer cases, clinical pipeline activity, and anticipated regulatory ...